Translating therapies for Huntington's disease from genetic animal models to clinical trials.
about
Large animal models of rare genetic disorders: sheep as phenotypically relevant models of human genetic diseaseCognitive Training at a Young Age Attenuates Deficits in the zQ175 Mouse Model of HD.Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior.PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's DiseaseComprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocyclineInhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's diseaseMouse models of Huntington's disease and methodological considerations for therapeutic trials.Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's diseaseCombination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Reduced creatine kinase as a central and peripheral biomarker in Huntington's diseaseTriterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's diseaseLongitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images.FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's diseasePharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's diseaseSpatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.Neuroprotection for Huntington's disease: ready, set, slowEnhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.Emerging drug therapies in Huntington's disease.Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease.Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.A low-cost, reliable, high-throughput system for rodent behavioral phenotyping in a home cage environment.
P2860
Q26795469-53230F11-DEB2-4C5F-AD06-ED5A9FB5690CQ27321673-13383F3E-29C0-4E92-B617-2481C501FB89Q28504771-E8FD0E8C-4507-408A-8EC6-21572D07E302Q28547107-ACDF41EC-881B-4F19-9E1E-D038C4626111Q28748449-0208697B-251F-459F-B768-86EFA9E259CDQ28748849-B5077D8B-BD9F-444E-914D-0C1A01E81BDFQ30481208-E4B83119-6E6D-43ED-A355-57E6B8155990Q33327216-3332C31D-C58C-4529-BCC3-54D9B7D8C2D8Q33837238-AC73AD28-252E-4B20-8143-2C6DC175F044Q33945688-21F9ECB4-BC05-4DAE-9925-D97C3C046368Q34043950-C366F02B-8284-4DD0-8525-8036365C1CF1Q34090021-F480D3A6-FA58-415D-B7FA-96B2E5E9C388Q34212651-6FD111C9-6E60-4506-8CA0-92616253148BQ35750228-8608892E-F2D5-4344-AD2D-A5227EC074CFQ35874667-3210DAE9-3992-443A-A505-5F8EAEA9E6EEQ36606399-57D41397-3212-4AB4-838B-BC0523E9F2AFQ37131243-20ADC017-8DC6-48FF-BB34-34AB8493A3E8Q37368003-744E579C-AC15-433C-9F44-CA28C572C27BQ37488273-A77B4A70-5F11-48E5-B0FF-030D7324153AQ38515686-9652276C-E409-494A-8576-A083032CCF4CQ38663090-B49825F1-63EA-4A44-B48C-5894C1B6A326Q41440495-E6037E04-E8A2-49C0-B5D6-4D90E27FD858
P2860
Translating therapies for Huntington's disease from genetic animal models to clinical trials.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Translating therapies for Hunt ...... mal models to clinical trials.
@ast
Translating therapies for Hunt ...... mal models to clinical trials.
@en
type
label
Translating therapies for Hunt ...... mal models to clinical trials.
@ast
Translating therapies for Hunt ...... mal models to clinical trials.
@en
prefLabel
Translating therapies for Hunt ...... mal models to clinical trials.
@ast
Translating therapies for Hunt ...... mal models to clinical trials.
@en
P2860
P356
P1433
P1476
Translating therapies for Hunt ...... mal models to clinical trials.
@en
P2860
P304
P356
10.1602/NEURORX.1.3.298
P577
2004-07-01T00:00:00Z